|
Probl Tuberk. 2003;(7):42-7. |
Immunological changes in patients with pulmonary
tuberculosis during glutoxim therapy.
[Article in Russian].
Knoring BE, Avetisian
AO, El'kin AV, Kozhemiakin LA, Simbirtsev AS, Sakharova IIa, Loginova GP, Pigareva NV, Levashev IuN.
The paper deals with the effect of glutoxim included into a preoperative
preparation regimen on immunological parameters in patients with fibrocavernous
pulmonary tuberculosis. On admission, all the patients had inadequate cellular
immunity and activated humoral immunity. After termination of a course of
glutoxim therapy, there was an increase in the baseline low values of
lymphocytic proliferative activity, in the count of mature T lymphocytes, and
in the production of IL-2 induced by phytohemagglutinin. At the same time the
similar parameters remained unchanged in the control group. The drug exerted
the most noticeable stimulating effect on cellular immunity in patients with a
limited process. Glutoxim produced no noticeable effect on humoral immunity.
The immunomodulating effect of glutoxim was followed by improvement of the
clinical and X-ray pictures of the disease. In glutoxim-treated patients with
baseline immunological disorders, progression was found to occur 1.5-2 times
more infrequently than in the control group. Indications for the use of
glutoxim in the treatment of tuberculosis are specified on the basis of the
baseline immunological parameters of each patient.
For more references:
Dr. Giorgio Castello
Corso Torino, 32/6
16129 – Genova (Italy)
Tel: +39.010.58.94.95
Mobil
phone: +39.335.628.34.24
e-mail:
castello@tiopoietine.info